Why Is Biohaven Stock Falling On Thursday?
1. FDA delayed the review date for troriluzole by three months. 2. Troriluzole could become the first approved treatment for spinocerebellar ataxia. 3. Biohaven's shares dropped 14.3% following the PDUFA extension news. 4. FDA's decision now expected in Q4 2025 instead of Q3. 5. William Blair maintains an Outperform rating, citing potential for approval.